Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $30
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $24 to $30.
Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $24 to $30.